An interventional study of PHE-diet in Phenylketonurias, sponsored by Klaus Parhofer. Terminated at 1 site in Germany. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Klaus Parhofer · Not applicable, Interventional, and Treatment
The goal of this study is to evaluate if in adult patients with phenylketonuria (PKU) without strict metabolic control during the last 12 months, strict metabolic control for 8 weeks results in an improvement of cognitive function.
183 studies on the registry are indexed under Phenylketonurias; 38 are open to participants now.
This study's enrollment of 13 is below the median of 25 across 114 interventional studies indexed under Phenylketonurias.
Browse Phenylketonurias studies →This is the only study on the registry with Klaus Parhofer as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: PHE-diet
phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
Spatial working memory strategy index
cognitive function; scores range from 4 to 28, with lower scores representing better outcome
Time frame: 8 weeks
Reaction time
cognitive function; milliseconds, with faster times representing better outcome
Time frame: 8 weeks
Paired Associates Learning
cognitive function; scores range from 0 to 70, with lower scores indicating better outcome
Time frame: 8 weeks
Multitasking Test
cognitive function; scores range from 0 to 279, with lower scores indicating better outcome
Time frame: 8 weeks
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.